Cyclooxygenase-2 expression in right- and left-sided colon cancer: A rationale for optimization of cyclooxygenase-2 inhibitor therapy

Clinical Colorectal Cancer

Volumn 3, Issue 4, 2004, Pages 243-247

  Nasir, Aejaz ^a   Kaiser, Hans E ^b   Boulware, David ^a   Hakam, Ardeshir ^a   Zhao, Helena ^a   Yeatman, Timothy ^a   Barthel, James ^a   Coppola, Domenico ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ISSCO   (United States)

^c Diagnostic Laboratory Services   (United Kingdom)

Author keywords

APC gene; Hereditary nonpolyposis colon cancer; Immunohistochemistry; Nonsteroidal antiinflammatory drugs

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME INHIBITION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PATIENT SELECTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM;

EID: 1842556606     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.005     Document Type: Article

References (60)

1. Rao CV, Indranie C, Simi B, et al. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62:165-170.
2. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002; 13:127-137.
3. Dannenberg AJ, Zakim D. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Semin Oncol 1999; 26:499-504.
4. Patti R, Gumired K, Reddanna P, et al. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer Lett 2002; 180:13-21.
5. Kawabe A, Shimada Y, Uchida S, et al. Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression. Oncology 2002; 62:46-54.
6. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348:919-932.
7. Moolgavkar SH, Luebeck EG. Multistage carcinogenesis: population-based model for colon cancer. J Natl Cancer Inst 1992; 84:610-618.
8. Nakamura Y, Nishisho I, Kinzler KW, et al. Mutations of the adenomatous polyposis coli gene in familial polyposis coli patients and sporadic colorectal tumors. Princess Takamatsu Symp 1991; 22:285-292.
9. Higashidani Y, Tamura S, Morita T, et al. Analysis of K-ras codon 12 mutation in flat and nodular variants of serrated adenoma in the colon. Dis Colon Rectum 2003; 46:327-332.
10. Cho KR, Oliner JD, Simons JW, et al. The DCC gene: Structural analysis and mutations in colorectal carcinomas. Genomics 1994; 19:525-531.
11. Salovaara R, Roth S, Loukola A, et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 2002; 51:56-59.
12. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996; 13:343-346.
13. Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature 1997; 389:300-305.
14. Irby RB, Mao W, Coppola D, et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999; 21:187-190.
15. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: Genetics and clinical implications. Ann Intern Med 2003; 138:560-570.
16. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003; 21:1174-1179.
17. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58:4823-4826.
18. Hao X, Bishop AE, Wallace M, et al. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 187:295-301.
19. Kojima M, Morisaki T, Uchiyama A, et al. Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol 2001; 8:458-465.
20. Masunaga R, Kohno H, Dhar DK, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6:4064-4068.
21. Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282:1254-1257.
22. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55:3785-3789.
23. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60:293-297.
24. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311.
25. Keller JJ, Offerhaus GJ, Drillenburg P, et al. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin Cancer Res 2001; 7:4000-4007.
26. Hsi LC, Angerman-Stewart J, Eling TE. Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translation level. Carcinogenesis 1999; 20:2045-2049.
27. Ponz de Leon M, Di Gregorio C. Pathology of colorectal cancer. Dig Liver Dis 2001; 33:372-388.
28. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85:200-206.
29. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 2002; 21:155-164.
30. Nasir A, Fernandez PM, Chughtai OR, et al. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms. In Vivo 2002; 16:501-509.
31. Jacoby RF, Seibert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60:5040-5044.
32. Sheng H, Shao J, Kirkland SC, et al. Inhibition of humans colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99:2254-2259.
33. Dubois RN. Review article: Cyclooxygenase - a target for colon cancer prevention. Aliment Pharmacol Ther 2000; 14(suppl 1):64-67.
34. El Hajjar D, Javle M, Lawrence D, et al. Cyclooxygenase (COX-2) expression before and after chemotherapy in rectal cancer. Proc Am Soc Clin Oncol 2003; 22:377 (Abstract #1514).
35. Rahme E, Barkun AN, Toubouti YM, et al. Specific COX-2 inhibitors Rofecoxib and Celecoxib may prevent colorectal adenomas occurrence and recurrence. A nested case-control study, Paper presented at: Digestive Disease Week, May 17-22, 2003, Orlando, FL.
36. Yamazaki R, Kusunoki N, Matsuzaki T, et al. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Let 2002; 531:278-284.
37. Oshima M, Taketo MM. COX selectivity and animal models for colon cancer. Curr Pharm Des 2002; 8:1021-1034.
38. Kawai N, Tsujii M, Tsuji S. Cyclooxygenases and colon cancer. Prostaglandins Other Lipid Mediat 2002; 68-69:187-196.
39. Feleszko W, Jalili A, Olszewska D, et al. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Res 2002; 9:879-885.
40. Fukutake M, Nakatsugi S, Isoi T, et al. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998; 19:1939-1942.
41. North GL. Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann Pharmacother 2001; 35:1638-1643.
42. Hartwich J, Konturek SJ, Pierzchalski P, et al. Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2. Med Sci Monit 2001; 7:1171-1181.
43. Ricciardiello K, Roda E, Bazzolin F. Chemoprevention in colorectal neoplasias: What is practical and feasible? Dig Dis 2002; 20:70-72.
44. Rex DK. Screening for colon cancer and evaluation of chemoprevention with coxibs. J Pain Symptom Manage 2002; 23(suppl 4):S41-S50.
45. Nagatsuka I, Yamada N, Shimizu S, et al. Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int J Cancer 2002; 100:515-519.
46. Moran EM. Epidemiological and clinical aspects of nonsteriodal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002; 21:193-201.
47. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduced proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62:625-631.
48. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apedelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61:1733-1740.
49. Goldman AP, Williams CS, Sheng H, et al. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998; 19:2195-2199.
50. Nakatsugi S, Fukutake M, Takahashi M, et al. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res 1997; 88:1117-1120.
51. Husain SS, Szabo IL, Tamawski AS. NSAID inhibition of GI cancer growth: Clinical implications and molecular mechanisms of action. Am J Gastroenterol 2002; 97:542-553.
52. Yao M, Lam EC, Kelly CR, et al. Cyclooxygenase-2 (COX-2) inhibition retards tumor progression by reducing cell proliferation and invasive potential, Paper presented at: Digestive Disease Week, May 17-22, 2003. Orlando, FL.
53. Chen WS, Wei SJ, Liu JM, et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001; 91:894-899.
54. Lipsky PE. The clinical potential of cyclooxygenase-2-specific inhibitors. Am J Med 199; 106:51S-57S.
55. Don XX, Mai M, Ogino T. [A clinicopathological study on colonic carcinomas arising from right side colon]. Gan No Risho 1989; 35:1421-1428.
56. Gonzalez EC, Roetzheim RG, Ferrante JM, et al. Predictors of proximal vs. distal colorectal cancers. Dis Colon Rectum 2001; 44:251-258.
57. Karnes WE, Jr. Implications of low COX-2 expression in colorectal neoplasms with defective DNA mismatch repair. J Cell Biochem 2000; 77(suppl):23-27.
58. Hull MA, Fenwick SW, Chapple KS, et al. Cyclooxygenase-2-expression in colorectal cancer liver metastases. Clin Exp Metastasis 2000; 18:21-27.
59. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002; 97:1037-1041.
60. Yamauchi T, Watanabe M, Kubota T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002; 45:98-103.